DE69230224D1 - Potenzierung von nmda-antagonisten - Google Patents

Potenzierung von nmda-antagonisten

Info

Publication number
DE69230224D1
DE69230224D1 DE69230224T DE69230224T DE69230224D1 DE 69230224 D1 DE69230224 D1 DE 69230224D1 DE 69230224 T DE69230224 T DE 69230224T DE 69230224 T DE69230224 T DE 69230224T DE 69230224 D1 DE69230224 D1 DE 69230224D1
Authority
DE
Germany
Prior art keywords
potentization
nmda antagonists
antagonists
nmda
poteniating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69230224T
Other languages
English (en)
Other versions
DE69230224T2 (de
Inventor
Ian A Mcdonald
Bruce M Baron
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Merrell Dow Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharmaceuticals Inc filed Critical Merrell Dow Pharmaceuticals Inc
Publication of DE69230224D1 publication Critical patent/DE69230224D1/de
Application granted granted Critical
Publication of DE69230224T2 publication Critical patent/DE69230224T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
DE69230224T 1991-12-20 1992-12-01 Potenzierung von nmda-antagonisten Expired - Fee Related DE69230224T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/811,204 US5318985A (en) 1991-12-20 1991-12-20 Potentiation of NMDA antagonists
PCT/US1992/010354 WO1993012780A1 (en) 1991-12-20 1992-12-01 Potentiation of nmda antagonists

Publications (2)

Publication Number Publication Date
DE69230224D1 true DE69230224D1 (de) 1999-12-02
DE69230224T2 DE69230224T2 (de) 2000-04-13

Family

ID=25205874

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69230224T Expired - Fee Related DE69230224T2 (de) 1991-12-20 1992-12-01 Potenzierung von nmda-antagonisten

Country Status (10)

Country Link
US (2) US5318985A (de)
EP (1) EP0617616B1 (de)
JP (1) JPH07504890A (de)
AT (1) ATE185969T1 (de)
AU (1) AU667333B2 (de)
CA (1) CA2124799A1 (de)
DE (1) DE69230224T2 (de)
DK (1) DK0617616T3 (de)
NZ (1) NZ246114A (de)
WO (1) WO1993012780A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5189054A (en) * 1990-11-02 1993-02-23 Merrell Dow Pharmaceuticals Inc. 3-amidoindolyl derivatives and pharmaceutical compositions thereof
GB9716657D0 (en) 1997-08-07 1997-10-15 Zeneca Ltd Chemical compounds
GB9803226D0 (en) 1998-02-17 1998-04-08 Zeneca Ltd Chemical compounds
GB9902453D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB9902459D0 (en) * 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB9902461D0 (en) * 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB9902455D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB9902452D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB0000625D0 (en) 2000-01-13 2000-03-01 Zeneca Ltd Chemical compounds
US7375136B2 (en) * 2001-03-08 2008-05-20 Emory University pH-dependent NMDA receptor antagonists
KR20100045983A (ko) 2007-06-29 2010-05-04 에모리 유니버시티 신경보호를 위한 ｎｍｄａ 수용체 길항물질
EP3427729A1 (de) * 2017-07-13 2019-01-16 Paris Sciences et Lettres - Quartier Latin Probenecid zur behandlung von epileptischen erkrankungen, störungen oder zuständen

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2608507A (en) * 1949-08-20 1952-08-26 Sharp & Dohme Inc Dialkyl sulfamyl benzoic acids
US2608508A (en) * 1949-08-20 1952-08-26 Sharp & Dohme Inc N-amylsulfamyl benzoic acids
JPS5756425A (en) * 1980-09-20 1982-04-05 Santen Pharmaceut Co Ltd Hypotensor
US4960786A (en) * 1989-04-24 1990-10-02 Merrell Dow Pharmaceuticals Inc. Excitatory amino acid antagonists
US5095009A (en) * 1990-04-11 1992-03-10 Merrell Dow Pharmaceuticals Inc. NMDA antagonists
US5051442A (en) * 1990-04-25 1991-09-24 Merrell Dow Pharmaceuticals Inc. 3-indolyl thioacetate derivatives and NMDA receptor antagonistic use thereof
DE4021545A1 (de) * 1990-07-06 1992-01-16 Engineering Der Voest Alpine I Verfahren und vorrichtung zum herstellen von kunststoffaeden oder -fasern aus polymeren, insbesondere polyamid, polyester oder polypropylen
ES2088011T3 (es) * 1990-07-16 1996-08-01 Merrell Pharma Inc Antagonistas de aminoacidos excitadores.
ES2089511T3 (es) * 1991-02-27 1996-10-01 Merrell Pharma Inc Dihidroquinolina antagonistas de nmda.
AU643365B2 (en) * 1991-02-28 1993-11-11 Aventisub Ii Inc. NMDA antagonists
CA2115442C (en) * 1991-09-09 2003-09-23 Christopher Franklin Bigge Pharmaceutical preparation containing an uricosuric agent and an excitatory amino acid antagonist

Also Published As

Publication number Publication date
US5489579A (en) 1996-02-06
ATE185969T1 (de) 1999-11-15
CA2124799A1 (en) 1993-07-08
AU667333B2 (en) 1996-03-21
EP0617616A1 (de) 1994-10-05
DK0617616T3 (da) 2000-04-17
JPH07504890A (ja) 1995-06-01
AU3150993A (en) 1993-07-28
DE69230224T2 (de) 2000-04-13
EP0617616B1 (de) 1999-10-27
US5318985A (en) 1994-06-07
WO1993012780A1 (en) 1993-07-08
NZ246114A (en) 1995-10-26

Similar Documents

Publication Publication Date Title
DK0841928T3 (da) Sustained release-formulering af d-threo-methylphenidat
PT641343E (pt) Derivados de 4-mercaptoacetilamino-¬2|benzazapinona (3) e a sua utilizacao como inibidores de encefalinase
DE69230224D1 (de) Potenzierung von nmda-antagonisten
NO930035L (no) Eksitatoriske aminosyreantagonister
ATE79637T1 (de) Substituierte alkylamide von teicoplaninverbindungen.
DK0526478T3 (da) 3-Indolyl-thioacetat-derivater
ES2089511T3 (es) Dihidroquinolina antagonistas de nmda.
NO890803D0 (no) Fremgangsmaate for fremstilling av trisubstituerte aminer.
FI912382A (fi) Menetelmä heterosyklisten NMDA-antagonistien valmistamiseksi
GR1001566B (el) Μέ?οδος παρασκευής νέων παραγώγων βενζοφουρανυλιμιδαζόλης.
YU48719B (sh) Lizin so 6-hloro-5-fluoro-3-(2-tenoil)-2-oksindol-1-karboksamida
GR1001368B (el) Φαρμακευτικοί φορείς.
FR2640414B1 (fr) Electro-aimant de coupure alimente en courant alternatif
BG43004A3 (en) Method for preparing condensed as- triazines
JO1661B1 (en) Benzimazole compounds carry therapeutically effective fluorescent alternatives and a method for their preparation and use
SE9102571D0 (sv) A novel method of generating clones for the expression of unfused proteins
ATE92755T1 (de) Phenol-thioether als inhibitoren von 5lipoxygenase.
SE8802014D0 (sv) Sett for impregnering av lignocellulosamaterial
ATE86481T1 (de) Dosisform zur verabreichung von calciumantagonisten.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee